Do glutamatergic agents represent a new class of antidepressant drugs? Part 1.
Sanacora
Gerard
G
Department of Psychiatry, Yale University, New Haven, CT 06519, USA. Gerard.sanacora@yale.edu
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D004195:Disease Models, Animal; D015195:Drug Design; D006801:Humans; D009410:Nerve Degeneration / Q000188:drug therapy / Q000503:physiopathology; D019636:Neurodegenerative Diseases; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D018091:Receptors, AMPA / Q000187:drug effects / Q000502:physiology; D018094:Receptors, Metabotropic Glutamate / Q000187:drug effects / Q000502:physiology; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects / Q000502:physiology; D019782:Riluzole / Q000494:pharmacology / Q000627:therapeutic use; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology
D000928:Antidepressive Agents; D018696:Neuroprotective Agents; D018091:Receptors, AMPA; D018094:Receptors, Metabotropic Glutamate; D016194:Receptors, N-Methyl-D-Aspartate; D019782:Riluzole